Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics

news.bms.com/news/details/2025/Bristol-Myers-Squibb-Strengthens-and-Diversifies-Cell-Therapy-Portfolio-with-Acquisition-of-Orbital-Therapeutics/default.aspx

Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases
Transaction further strengthens BMS’s industry-leading cell therapy portfolio, expanding CAR T-cell access…

This story appeared on news.bms.com, 2025-10-10 16:26:11.497000.
The Entire Business World on a Single Page. Free to Use →